Granisetron transdermal - Kyowa Kirin International

Drug Profile

Granisetron transdermal - Kyowa Kirin International

Alternative Names: Sancuso; SP-01 - Solasia Pharma

Latest Information Update: 24 May 2017

Price : $50

At a glance

  • Originator ProStrakan
  • Developer Kyowa Hakko Kirin; Kyowa Kirin International; LG Life Sciences; NewBridge Pharmaceuticals; Solasia Pharma
  • Class Analgesics; Antiemetics; Azabicyclo compounds; Indazoles; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 24 May 2017 Granisetron is still under regulatory review for Chemotherapy induced nausea and vomiting (Prevention) in Malaysia (Transdermal) (Kyowa Hakko Kirin pipeline, May 2017)
  • 16 May 2017 Granisetron is still under regulatory review for Chemotherapy induced nausea and vomiting (Prevention) in China (Transdermal) (Solasia website, May 2017)
  • 16 May 2017 Launched for Chemotherapy induced nausea and vomiting (Prevention) in Macau and Singapore (Transdermal) before May 2017 (Kyowa Kirin website, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top